1. Home
  2. Targets
  3. hydrolase
  4. protease
  5. metalloprotease
  6. Angiotensin-converting enzyme

Tclin Angiotensin-converting enzyme

Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.

This gene encodes an enzyme involved in catalyzing the conversion of angiotensin I into a physiologically active peptide angiotensin II. Angiotensin II is a potent vasopressor and aldosterone-stimulating peptide that controls blood pressure and fluid-electrolyte balance. This enzyme plays a key role in the renin-angiotensin system. Many studies have associated the presence or absence of a 287 bp Alu repeat element in this gene with the levels of circulating enzyme or cardiovascular pathophysiologies. Multiple alternatively spliced transcript variants encoding different isoforms have been identified, and two most abundant spliced variants encode the somatic form and the testicular form, respectively, that are equally active. [provided by RefSeq, May 2010]

 Comments

Property Summary

Ligand Count 344
NCBI Gene PubMed Count 2,407
PubMed Score 30363.80
PubTator Score 16082.84

Knowledge Summary

Patent

No data available

TINX Plot

  Disease (7)

Disease Target Count Z-score Confidence
Hypertension 396 8.485 4.0
Coronary artery disease 268 7.63 3.8
Adenocarcinoma 122 0.0 0.0
Albuminuria 21 0.0 0.0
Allanson Pantzar McLeod syndrome 4 0.0 0.0
Alzheimer Disease 83 0.0 0.0
Arrhythmias, Cardiac 19 0.0 0.0
Atrial Fibrillation 124 0.0 0.0
Autistic Disorder 364 0.0 0.0
Berylliosis 28 0.0 0.0
Brain Ischemia 110 0.0 0.0
Carcinoma, Hepatocellular 228 0.0 0.0
Cardiovascular Diseases 59 0.0 0.0
Cerebral Hemorrhage 42 0.0 0.0
Coronary Disease 25 0.0 0.0
Coronary Restenosis 8 0.0 0.0
Cough 23 0.0 0.0
Death, Sudden 2 0.0 0.0
Diabetes Mellitus, Experimental 108 0.0 0.0
Diabetic Nephropathies 37 0.0 0.0
Drug Hypersensitivity 34 0.0 0.0
Gaucher Disease 4 0.0 0.0
Genetic Predisposition to Disease 27 0.0 0.0
Glomerulonephritis, IGA 34 0.0 0.0
Glycogen Storage Disease Type V 2 0.0 0.0
Heart failure 162 0.0 0.0
Hypertension, Pulmonary 37 0.0 0.0
Hypertrophy, Left Ventricular 24 0.0 0.0
Hypotension 82 0.0 0.0
Infant, Premature, Diseases 1 0.0 0.0
Infertility, Male 46 0.0 0.0
Kidney Diseases 114 0.0 0.0
Kidney Failure, Chronic 46 0.0 0.0
Lung Neoplasms 232 0.0 0.0
Lung diseases 50 0.0 0.0
MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3 1 0.0 0.0
Meningococcal Infections 4 0.0 0.0
Neoplasm Metastasis 168 0.0 0.0
Non-alcoholic Fatty Liver Disease 42 0.0 0.0
Pneumonia, Viral 1 0.0 0.0
Pre-Eclampsia 68 0.0 0.0
Prostatic Neoplasms 495 0.0 0.0
Psychoses, Substance-Induced 17 0.0 0.0
RENAL TUBULAR DYSGENESIS 4 0.0 0.0
Renal Insufficiency 90 0.0 0.0
Respiratory Tract Diseases 6 0.0 0.0
Severe acute respiratory syndrome 27 0.0 0.0
Staphylococcal Infections 5 0.0 0.0
Stomach Neoplasms 300 0.0 0.0
Stroke 33 0.0 0.0
Vascular System Injuries 9 0.0 0.0
Weight Gain 100 0.0 0.0
Disease Target Count P-value
non-small cell lung cancer 2890 6.8e-17
lung adenocarcinoma 2716 1.1e-10
facioscapulohumeral dystrophy 288 4.0e-02
Disease Target Count Z-score Confidence
Carcinoma 11493 0.0 0.9
Disease Target Count Z-score Confidence
Kidney disease 430 7.518 3.8
Heart disease 306 7.464 3.7
sarcoidosis 370 7.064 3.5
diabetes mellitus 1728 6.992 3.5
Angioedema 38 6.617 3.3
Cerebrovascular disease 238 6.449 3.2
Atherosclerosis 291 5.587 2.8
Lung disease 142 5.381 2.7
Lipid metabolism disorder 114 4.794 2.4
Obesity 678 4.643 2.3
Anemia 365 4.472 2.2
Dementia 175 4.416 2.2
Peripheral vascular disease 87 4.275 2.1
Hyperglycemia 137 4.267 2.1
Uveitis 103 4.194 2.1
Connective tissue disease 62 4.183 2.1
Diabetic retinopathy 56 4.111 2.1
Cancer 2499 4.107 2.1
Renal artery disease 3 4.104 2.1
Hypersensitivity reaction type II disease 253 4.088 2.0
Hypokalemia 52 3.877 1.9
Asthma 385 3.83 1.9
Peripheral artery disease 10 3.731 1.9
Impotence 42 3.72 1.9
Urinary tract obstruction 11 3.7 1.8
Intermittent claudication 20 3.692 1.8
Hyperaldosteronism 35 3.655 1.8
Neuropathy 261 3.576 1.8
Exanthem 37 3.535 1.8
Transient Cerebral Ischemia 25 3.527 1.8
Liver disease 237 3.474 1.7
Allergic hypersensitivity disease 126 3.433 1.7
Gaucher's disease 26 3.423 1.7
Conn's syndrome 22 3.417 1.7
Aortic aneurysm 38 3.409 1.7
Urticaria 67 3.381 1.7
C1 inhibitor deficiency 8 3.375 1.7
Autosomal dominant polycystic kidney disease 31 3.299 1.6
Migraine 83 3.282 1.6
tuberculosis 2010 3.24 1.6
Vasculitis 80 3.202 1.6
Hyperinsulinism 133 3.181 1.6
Substance abuse 59 3.131 1.6
Choroiditis 5 3.118 1.6
Hypertensive encephalopathy 3 3.116 1.6
Hypercalcemia 59 3.067 1.5
Lymphatic system disease 15 3.041 1.5
Alport syndrome 21 3.002 1.5
Disease Target Count
Kidney Failure 111
Renal dysplasia 28

Expression

  Differential Expression (3)

Disease log2 FC p
facioscapulohumeral dystrophy 1.800 4.0e-02
lung adenocarcinoma -1.500 1.1e-10
non-small cell lung cancer -1.692 6.8e-17

Synonym

Accession P12821 B0LPF0 B4DXI3 E7EU16 P22966 Q53YX9 Q59GY8 Q7M4L4 ACE
Symbols DCP
ACE1
DCP1
CD143

Gene

ACE

PANTHER Protein Class (3)

  Ortholog (11)

Species Source Disease
Inparanoid OMA EggNOG
Inparanoid EggNOG
Inparanoid OMA EggNOG
Inparanoid OMA EggNOG
OMA EggNOG
Inparanoid EggNOG
Inparanoid OMA EggNOG
OMA EggNOG
Inparanoid OMA EggNOG
Inparanoid OMA EggNOG
Inparanoid OMA EggNOG

 UniProt Keyword (23)

See all...

 GO Function (14)

See all...

 GO Component (8)

 GO Process (33)

See all...

 Compartment GO Term (92)

See all...

 IMPC Phenotype (7)

 OMIM Phenotype (6)

 MGI Phenotype (12)

See all...

 GWAS Trait (7)

 HCA RNA Cell Line (43)

See all...

 CSPA Cell Line (10)

Pathway (39)

See all...

PDB (35)

Drug (19)

Structure of enalapril

enalapril
pIC50 4.30

Structure of enalaprilat

enalaprilat
pIC50 7.50

Structure of trandolapril

trandolapril
pIC50 8.12

Structure of ramipril

ramipril
pKi 8.34

Structure of lisinopril

lisinopril
pIC50 8.92

Structure of cilazapril

cilazapril
pIC50 8.70

Structure of captopril

captopril
pKi 8.70

Structure of benazepril

benazepril
pIC50 6.51

Structure of spirapril

spirapril
pIC50 9.10

Structure of perindopril

perindopril
pIC50 8.82

Structure of imidapril

imidapril
pIC50 5.00

Structure of temocapril

temocapril

Structure of delapril

delapril
pKi 9.97

Structure of alacepril

alacepril

Structure of zofenopril

zofenopril
pIC50 9.40

Structure of quinapril

quinapril
pIC50 8.08

Structure of moexipril

moexipril
pIC50 8.59

Structure of fosinopril

fosinopril
pIC50 9.00

Structure of racecadotril

racecadotril
pIC50 6.50

Ligand (315)

Structure of CHEMBL401397

CHEMBL401397
pKi 6.00

Structure of CHEMBL290328

CHEMBL290328
pIC50 6.00

Structure of CHEMBL558146

CHEMBL558146
pIC50 6.00

Structure of CHEMBL398771

CHEMBL398771
pKi 6.02

Structure of CHEMBL298827

CHEMBL298827
pIC50 6.07

Structure of CHEMBL560685

CHEMBL560685
pIC50 6.08

Structure of CHEMBL271224

CHEMBL271224
pKi 6.08

Structure of CHEMBL55583

CHEMBL55583
pIC50 6.10

Structure of CHEMBL254493

CHEMBL254493
pKi 6.11

Structure of CHEMBL254495

CHEMBL254495
pKi 6.13

Structure of CHEMBL147755

CHEMBL147755
pIC50 6.14

Structure of CHEMBL171850

CHEMBL171850
pIC50 6.15

Structure of CHEMBL89547

CHEMBL89547
pIC50 6.16

Structure of CHEMBL3037879

CHEMBL3037879
pIC50 6.16

Structure of CHEMBL85175

CHEMBL85175
pIC50 6.16

Structure of CHEMBL404117

CHEMBL404117
pKi 6.16

Structure of CHEMBL128223

CHEMBL128223
pIC50 6.19

Structure of CHEMBL257229

CHEMBL257229
pKi 6.21

Structure of CHEMBL3264007

CHEMBL3264007
pIC50 6.23

Structure of CHEMBL1907762

CHEMBL1907762
pIC50 6.24

Gene RIF (2870)

AA Sequence 

MGAASGRRGPGLLLPLPLLLLLPPQPALALDPGLQPGNFSADEAGAQLFAQSYNSSAEQVLFQSVAASWA      1 - 70
HDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRIIGAVRTLGSANLPLAKRQQY     71 - 140
NALLSNMSRIYSTAKVCLPNKTATCWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYEDFTAL    141 - 210
SNEAYKQDGFTDTGAYWRSWYNSPTFEDDLEHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAH    211 - 280
LLGDMWAQSWENIYDMVVPFPDKPNLDVTSTMLQQGWNATHMFRVAEEFFTSLELSPMPPEFWEGSMLEK    281 - 350
PADGREVVCHASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAI    351 - 420
GDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPPSRYNF    421 - 490
DWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQFHEALCKEAGYEGPLHQCDIY    491 - 560
RSTKAGAKLRKVLQAGSSRPWQEVLKDMVGLDALDAQPLLKYFQPVTQWLQEQNQQNGEVLGWPEYQWHP    561 - 630
PLPDNYPEGIDLVTDEAEASKFVEEYDRTSQVVWNEYAEANWNYNTNITTETSKILLQKNMQIANHTLKY    631 - 700
GTQARKFDVNQLQNTTIKRIIKKVQDLERAALPAQELEEYNKILLDMETTYSVATVCHPNGSCLQLEPDL    701 - 770
TNVMATSRKYEDLLWAWEGWRDKAGRAILQFYPKYVELINQAARLNGYVDAGDSWRSMYETPSLEQDLER    771 - 840
LFQELQPLYLNLHAYVRRALHRHYGAQHINLEGPIPAHLLGNMWAQTWSNIYDLVVPFPSAPSMDTTEAM    841 - 910
LKQGWTPRRMFKEADDFFTSLGLLPVPPEFWNKSMLEKPTDGREVVCHASAWDFYNGKDFRIKQCTTVNL    911 - 980
EDLVVAHHEMGHIQYFMQYKDLPVALREGANPGFHEAIGDVLALSVSTPKHLHSLNLLSSEGGSDEHDIN    981 - 1050
FLMKMALDKIAFIPFSYLVDQWRWRVFDGSITKENYNQEWWSLRLKYQGLCPPVPRTQGDFDPGAKFHIP   1051 - 1120
SSVPYIRYFVSFIIQFQFHEALCQAAGHTGPLHKCDIYQSKEAGQRLATAMKLGFSRPWPEAMQLITGQP   1121 - 1190
NMSASAMLSYFKPLLDWLRTENELHGEKLGWPQYNWTPNSARSEGPLPDSGRVSFLGLDLDAQQARVGQW   1191 - 1260
LLLFLGIALLVATLGLSQRLFSIRHRSLHRHSHGPQFGSEVELRHS                           1261 - 1306
//

Text Mined References (2416)

PMID Year Title